Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CSK drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CSK Recombinant Protein (WT & Mutants) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for enzymatic assays. |
View CSK Products |
| Gene Delivery | CSK Promise-ORF / Lentivirus Full-length ORF for stable cell lines and intracellular expression. |
View CSK Products |
| Benchmark Ab | Anti-CSK Recombinant Antibody Recombinant positive control for Western Blot and IP. |
View CSK Products |
| Validator | CSK siRNA Set For knockdown verification and functional validation. |
View CSK Products |
| Related Target A | LCK Primary downstream substrate of CSK; critical node in T-cell receptor activation. |
View LCK Products |
| Related Target B | PAG1 Adaptor protein that recruits CSK to the lipid rafts to inhibit Src family kinases. |
View PAG1 Products |
| Related Target C | SRC Proto-oncogene tyrosine-protein kinase Src, negatively regulated by CSK phosphorylation. |
View SRC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Kinase Selectivity Profiling (CSK vs. SFKs) | Recombinant CSK and SFK panel (Src, Lck, Fyn) available with high purity (>95%) and sequence verification. |
| Intracellular Target Engagement | CSK Lentiviral vectors designed for stable cell line expression to verify downstream phosphorylation in cell-based assays. |
| Lack of Controls | Sequence-verified clinical-grade benchmark antibodies and siRNA sets included for assay calibration. |
| False Positives in Small Molecule Screens | Kinase-dead mutant (e.g., K222R) and gatekeeper mutant proteins available for counter-screening. |
Live CSK R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CSK therapeutics is intensifying, with major players shifting focus from traditional multi-kinase inhibitors to highly selective small molecules and targeted protein degraders (PROTACs). As first-generation immunotherapies encounter resistance, the next wave of R&D is targeting CSK to release the "brakes" on T-cell receptor (TCR) signaling, amplifying anti-tumor immune responses.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Pfizer, Novartis, Academic Institutions | Solid Tumors, Autoimmune Diseases | Selectivity Assay (Need Mutant vs WT Proteins) |
| PROTACs (Degraders) | Biotech Startups, Target Degradation Specialists | Hematological Malignancies, Immunotherapy | Target Engagement Validation (Need high-purity WT CSK and Lentivirus) |
| Combination Therapies | Combination with PD-1/PD-L1 inhibitors | Refractory Solid Tumors | Downstream Pathway Validation (Need Lck and PAG1 proteins) |